The Latin American liver cancer treatment market is expected to register a CAGR of nearly 7.9% during the forecast period. Changes in the current lifestyle of individuals led to the exposure of a large amount of population to the risk factors that contribute to liver cancer. The risk factors include hepatitis (caused by either the hepatitis B or hepatitis C virus), type-2 diabetes, metabolic disorders, excess body weight, alcohol consumption, and tobacco smoking. It has also been observed that liver cancer risk increases substantially with the increase in one’s body mass index (BMI). According to the OECD Obesity Update 2017, obesity levels are particularly high in Latin American countries. For example, in Mexico, 32.4% of males aged 15 years and over are obese as of 2017, and nearly 39% of the population is projected to become obese by 2030. Thus, owing to the above factors, the market is expected to show growth in the near future.
Key Market Trends
Hepatocellular Carcinoma Segment is Expected to Hold a Major Share in the Latin America Liver Cancer Treatment Market
Hepatocellular carcinoma is the most common form of liver cancer, which mostly occurs in people suffering from chronic liver disease, like cirrhosis. Hepatocellular carcinoma is one of the major causes leading to cancer-related deaths, globally. It is observed that the developing countries of the Latin American region have higher incidence rates of hepatocellular carcinoma than the developed countries, due to the disparity in the major risk factors, such as hepatitis C virus (HCV) and hepatitis B virus (HBV) infections, causing hepatocellular carcinoma in those regions. With the increase in the incidence of hepatocellular carcinoma, liver cancer therapeutics is expected to have huge demand. Hence, the rising incidence of cancer and high unmet medical needs are the major factors driving the market in the forecast period.
The Latin American liver cancer treatment market is consolidated, with some major players controlling the major share of the market, especially in the diagnostics space. Liver cancer diagnostics are majorly dependent on high-cost diagnostic imaging modalities, such as MRI, CT, and PET scanners. There are few major players in the global market, and due to the low volume of demand in Latin American countries, the concentration of medical device manufacturers is even lower. In the Latin American therapeutic space, several niche players operate, and various clinical trials are underway. Some of the companies that are currently dominating the market are Bayer AG, Bristol-Myers Squibb Company, Merck & Co., Inc, Eisai Inc., Exelixis Inc., Alnylam Pharmaceuticals Inc., Eli Lilly And Co., Onyx Pharmaceuticals Inc., and Pfizer Inc.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support